Monodisperse nanoparticle assembly with tunable structure, composition and properties can be taken as a superstructured building block for the construction of hierarchical nanostruc tures from the bottom up, which als...Monodisperse nanoparticle assembly with tunable structure, composition and properties can be taken as a superstructured building block for the construction of hierarchical nanostruc tures from the bottom up, which also represents a great challenge in nanotechnology. Here we report on a facile and controllable method that enables a high yield fabricatioa of uniform gold nanoparticle （AuNP） coresatellites with definable number （in average） of the satellite particles and tunable coretosatellite distance. The formation of the coresatellite nanostruc tures is driven by programmable DNAbasepairing, with the resulting nanocomplexes being isolatable via gel electrophoresis. By rationally controlling the DNA coverages on the core and shell particles, high production yields are achieved for the assembly/isolation process. As well, benefiting from a minimum DNA coverage on the satellite AuNPs, a strong affinity is observed for the asprepared coresatellites to get adsorbed on proteincoated graphene ox ide, which allows for a twodimensional hierarchical assembly of the coresatellite structures. The resulting hierarchical nanoassemblies are expected to find applications in various areas, including plasmonics, biosensing, and nanocatalysis. The method should be generalizable to make even more complicated and higherorder structures by making use of the structural programmability of DNA molecules.展开更多
In the pathogenesis of major depressive disorder, chronic stress-related neuroinflammation hinders favorable prognosis and antidepressant response. Mitochondrial DNA may be an inflammatory trigger, after its release f...In the pathogenesis of major depressive disorder, chronic stress-related neuroinflammation hinders favorable prognosis and antidepressant response. Mitochondrial DNA may be an inflammatory trigger, after its release from stress-induced dysfunctional central nervous system mitochondria into peripheral circulation. This evidence supports the potential use of peripheral mitochondrial DNA as a neuroinflammatory biomarker for the diagnosis and treatment of major depressive disorder. Herein, we critically review the neuroinflammation theory in major depressive disorder, providing compelling evidence that mitochondrial DNA release acts as a critical biological substrate, and that it constitutes the neuroinflammatory disease pathway. After its release, mitochondrial DNA can be carried in the exosomes and transported to extracellular spaces in the central nervous system and peripheral circulation. Detectable exosomes render encaged mitochondrial DNA relatively stable. This mitochondrial DNA in peripheral circulation can thus be directly detected in clinical practice. These characteristics illustrate the potential for mitochondrial DNA to serve as an innovative clinical biomarker and molecular treatment target for major depressive disorder. This review also highlights the future potential value of clinical applications combining mitochondrial DNA with a panel of other biomarkers, to improve diagnostic precision in major depressive disorder.展开更多
文摘Monodisperse nanoparticle assembly with tunable structure, composition and properties can be taken as a superstructured building block for the construction of hierarchical nanostruc tures from the bottom up, which also represents a great challenge in nanotechnology. Here we report on a facile and controllable method that enables a high yield fabricatioa of uniform gold nanoparticle （AuNP） coresatellites with definable number （in average） of the satellite particles and tunable coretosatellite distance. The formation of the coresatellite nanostruc tures is driven by programmable DNAbasepairing, with the resulting nanocomplexes being isolatable via gel electrophoresis. By rationally controlling the DNA coverages on the core and shell particles, high production yields are achieved for the assembly/isolation process. As well, benefiting from a minimum DNA coverage on the satellite AuNPs, a strong affinity is observed for the asprepared coresatellites to get adsorbed on proteincoated graphene ox ide, which allows for a twodimensional hierarchical assembly of the coresatellite structures. The resulting hierarchical nanoassemblies are expected to find applications in various areas, including plasmonics, biosensing, and nanocatalysis. The method should be generalizable to make even more complicated and higherorder structures by making use of the structural programmability of DNA molecules.
基金supported by the National Natural Science Foundation of China,No.81971269 (to DP)the Science and Technology Commission of Shanghai,No.YDZX20213100001003 (to DP)。
文摘In the pathogenesis of major depressive disorder, chronic stress-related neuroinflammation hinders favorable prognosis and antidepressant response. Mitochondrial DNA may be an inflammatory trigger, after its release from stress-induced dysfunctional central nervous system mitochondria into peripheral circulation. This evidence supports the potential use of peripheral mitochondrial DNA as a neuroinflammatory biomarker for the diagnosis and treatment of major depressive disorder. Herein, we critically review the neuroinflammation theory in major depressive disorder, providing compelling evidence that mitochondrial DNA release acts as a critical biological substrate, and that it constitutes the neuroinflammatory disease pathway. After its release, mitochondrial DNA can be carried in the exosomes and transported to extracellular spaces in the central nervous system and peripheral circulation. Detectable exosomes render encaged mitochondrial DNA relatively stable. This mitochondrial DNA in peripheral circulation can thus be directly detected in clinical practice. These characteristics illustrate the potential for mitochondrial DNA to serve as an innovative clinical biomarker and molecular treatment target for major depressive disorder. This review also highlights the future potential value of clinical applications combining mitochondrial DNA with a panel of other biomarkers, to improve diagnostic precision in major depressive disorder.
